Compare BFH & IRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BFH | IRTC |
|---|---|---|
| Founded | 1996 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.9B |
| IPO Year | 2000 | 2016 |
| Metric | BFH | IRTC |
|---|---|---|
| Price | $90.72 | $107.65 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 15 | 13 |
| Target Price | $80.64 | ★ $197.92 |
| AVG Volume (30 Days) | ★ 539.7K | 490.9K |
| Earning Date | 04-23-2026 | 04-30-2026 |
| Dividend Yield | ★ 1.08% | N/A |
| EPS Growth | ★ 98.36 | 61.71 |
| EPS | ★ 4.15 | N/A |
| Revenue | ★ $4,521,400,000.00 | $747,138,000.00 |
| Revenue This Year | $53.25 | $19.60 |
| Revenue Next Year | $3.53 | $15.94 |
| P/E Ratio | $21.96 | ★ N/A |
| Revenue Growth | N/A | ★ 26.24 |
| 52 Week Low | $50.63 | $101.75 |
| 52 Week High | $99.13 | $210.01 |
| Indicator | BFH | IRTC |
|---|---|---|
| Relative Strength Index (RSI) | 57.14 | 40.23 |
| Support Level | $82.58 | N/A |
| Resistance Level | $99.13 | $126.41 |
| Average True Range (ATR) | 2.78 | 6.18 |
| MACD | 0.14 | -0.69 |
| Stochastic Oscillator | 72.90 | 27.27 |
Formed by a combination of JCPenney's credit card processing unit and The Limited's credit card bank business, Bread Financial is a provider of private-label and co-branded credit cards, loyalty programs, and marketing services. The company's most financially significant unit is its credit card business that partners with retailers to jointly market Bread's credit cards to their customers. The company also retains a minority interest in spun-off LoyaltyOne, which operates the largest airline miles loyalty program in Canada and offers marketing services to grocery chains in Europe and Asia.
iRhythm Holdings Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.